Lymphoma Treatment by Stage and Type

Lymphoma is not one disease with four stages. It is a large family, and NCI writes a separate treatment summary for each branch of it.

Two splits do most of the sorting.

The first is Hodgkin or non-Hodgkin. These are different diseases with different drugs.

The second applies within non-Hodgkin lymphoma. NCI divides it into indolent and aggressive. Indolent lymphoma grows slowly, often cannot be cured once widespread, and can be lived with for many years. NCI reports a median survival as long as 20 years. Aggressive lymphoma grows fast, and is treated with cure as the goal. More than 70 percent of people with aggressive non-Hodgkin lymphoma are cured.

That is why the same stage number means different things depending on which line above you are on.

This page explains how each branch is organised. It is not advice about your own care.

Lymphoma is staged with the Lugano classification. NCI notes it replaced the Ann Arbor system, which was agreed at a conference in 1971 and modified at Cotswolds 18 years later.

Broadly, stage I is one region, stage II is more than one region on the same side of the diaphragm, stage III crosses the diaphragm, and stage IV is widespread.

Bulk is recorded separately, and its definition varies by subtype. In Hodgkin lymphoma, bulky means a mass more than a third of the chest width, or larger than 10 cm. In diffuse large B-cell lymphoma, NCI says cut-offs from 5 cm to 10 cm have been used, with 10 cm recommended. In follicular lymphoma, 6 cm has been suggested.

The stage matters. It just does not decide the plan on its own.

For treatment, Hodgkin lymphoma is sorted into early favourable, early unfavourable and advanced disease. The early groups differ by adverse features such as bulk and the number of involved sites.

For early favourable disease, NCI lists a short course of ABVD on its own, or a shorter course of ABVD followed by involved-field radiation. The number of cycles and the radiation dose are set by the treating team against the risk group and the interim scan. ABVD is doxorubicin, bleomycin, vinblastine and dacarbazine.

Interim PET scanning is used to decide about radiation. In three trials, people with a Deauville score of 1 or 2 after two or three cycles could skip radiation with no significant loss of overall survival. Two of the three trials showed more relapses without it. In the GHSG HD16 trial, five-year progression-free survival was 93.4 percent with combined treatment and 86.1 percent with ABVD alone.

NCI describes that 7 to 13 percent difference as readable two ways. It is either a reason to give radiation, or a reason to give four or more cycles of chemotherapy and leave radiation out.

Advanced disease has changed recently. A trial of 994 people compared N-AVD with BV-AVD. N-AVD adds nivolumab, a checkpoint inhibitor, to doxorubicin, vinblastine and dacarbazine. BV-AVD adds brentuximab vedotin instead. Two-year progression-free survival was 92 percent with N-AVD against 83 percent with BV-AVD, and nerve damage was far less common. On that basis NCI describes N-AVD as the treatment of choice for stage III and IV classical Hodgkin lymphoma. Read it with the trial's frame attached: it enrolled people with advanced classical Hodgkin lymphoma from adolescence upward, reported in 2024, and follow-up is still short. Immune checkpoint drugs bring their own toxicities, and access and cost differ widely between health systems. Both drugs carry FDA approval for previously untreated stage III or IV classical Hodgkin lymphoma in combination with AVD. NCI adds that ABVD remains a viable option where cost matters.

Late effects deserve a conversation of their own here, because most people with Hodgkin lymphoma are cured and live for decades. Heart disease and infection were the leading non-lymphoma causes of death in a review of 20,007 people treated between 2000 and 2016. Fertility is mostly affected by alkylating regimens rather than ABVD.

Follicular lymphoma is the most common indolent type, making up about 20 percent of all non-Hodgkin lymphoma and as much as 70 percent of indolent cases.

Here is the part that surprises people. NCI says watchful waiting remains a standard of care at the first encounter, and again for slow, symptom-free relapse. Deferring treatment is a decision, not an absence of one.

When treatment is needed, NCI notes several options give equivalent overall survival at 5 to 10 years. Rituximab can be given alone or with chemotherapy. It can also be paired with lenalidomide to avoid chemotherapy toxicity. Obinutuzumab is another anti-CD20 antibody, useful when severe reactions to rituximab have occurred.

For early-stage indolent lymphoma, radiation alone can give long-lasting control within the treated field. NCI notes nearly half of people treated with radiation alone relapse outside that field within 10 years.

Later options include CD19-directed CAR T-cell therapy after two or more prior lines, and mosunetuzumab, a bispecific antibody approved for relapsed or refractory follicular lymphoma after two or more lines.

One thing to watch for is transformation. In a prospective study, 379 of 2,652 people, or 14 percent, transformed to a more aggressive lymphoma after a median 6.8 years. Rapid growth in one area, or growth that differs between sites, can be the sign. A repeat biopsy is how it is confirmed, and the treatment then changes to match the new type.

Diffuse large B-cell lymphoma is the common aggressive type. NCI reports that about 50 percent of people with advanced-stage disease are cured with doxorubicin-based chemotherapy plus rituximab.

For stage I and contiguous stage II disease, R-CHOP is the backbone, with or without involved-field radiation. R-CHOP is rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. For favourable, non-bulky early disease, NCI says a shortened course is sufficient, based on a trial of 592 people that found four cycles non-inferior to six. That applies to that particular group; how many cycles you are given depends on stage, bulk, risk score and response.

For noncontiguous stage II, III and IV disease, there are two standard regimens. Pola-R-CHP swaps vincristine for polatuzumab vedotin. NCI lists it for an International Prognostic Index score of 2 or more, which matches the FDA label. R-CHOP remains standard where polatuzumab is unavailable, unaffordable or unsuitable.

NCI adds a careful point about who benefits. In the POLARIX trial, the gain from Pola-R-CHP was concentrated in tumours of activated B-cell origin. For germinal centre B-cell tumours without a double-hit change, NCI says it is reasonable to use R-CHOP.

Relapse within a year of R-CHOP, or disease that never responded, carries a poor outlook with older approaches.

CAR T-cell therapy changed this. Axicabtagene ciloleucel and lisocabtagene maraleucel are both approved for large B-cell lymphoma refractory to first-line chemoimmunotherapy or relapsing within 12 months of it. Both compare favourably with chemotherapy followed by an autologous stem cell transplant in randomised trials. Both labels carry boxed warnings for cytokine release syndrome and for neurological toxicity, and treatment is given at accredited centres.

Other options NCI lists include bispecific antibodies. Epcoritamab and glofitamab are both approved for relapsed or refractory large B-cell lymphoma after two or more lines of therapy. Polatuzumab vedotin with bendamustine and rituximab is approved after at least two prior therapies. Tafasitamab with lenalidomide, loncastuximab tesirine and rituximab with lenalidomide are also on the list. Stem cell transplant remains an option, as does palliative radiation.

SEER reports five-year relative survival for 2016 through 2022.

For Hodgkin lymphoma: 92.7 percent at stage I, 95.4 percent at stage II, 87.7 percent at stage III and 82.8 percent at stage IV.

For non-Hodgkin lymphoma: 87.6 percent at stage I, 79.7 percent at stage II, 74.0 percent at stage III and 63.6 percent at stage IV.

The non-Hodgkin figures pool dozens of subtypes with very different outlooks. Ask what the number looks like for yours.

• Call 911 or go to an emergency department if you have confusion, difficulty speaking, or a seizure in the weeks after CAR T-cell therapy or a bispecific antibody. Also go if you have new weakness on one side, or if swelling of the face and neck comes with breathlessness. That swelling can mean a lymph node mass is pressing on the large vein above the heart.
• Phone the oncology line at once, not a same-day appointment, if you have a temperature of 100.4 F (38 C) or higher, or shaking chills, while on treatment. Lymphoma treatment strips out the white cells that fight infection, and CDC calls a fever during chemotherapy a medical emergency. If that line does not answer quickly, go to an emergency department and say you are on lymphoma treatment.
• Call 911 or go to an emergency department if chest pain starts, or breathlessness comes on suddenly or is present at rest.
• Call your care team the same day if you notice any other new symptom at all in the first weeks after CAR T-cell therapy or a bispecific antibody, including breathlessness that has built slowly on exertion.
• Call your care team within a day or two if a lump is growing quickly, especially one that appeared over days. Do the same for drenching night sweats, new itching all over, or weight loss you did not intend.

What Is Lymphoma?, Hodgkin vs Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and CAR T-Cell Therapy.

• https://www.cancer.gov/types/lymphoma/hp/adult-hodgkin-treatment-pdq
• https://www.cancer.gov/types/lymphoma/hp/aggressive-b-cell-lymphoma-treatment-pdq
• https://www.cancer.gov/types/lymphoma/hp/indolent-b-cell-lymphoma-treatment-pdq
• https://seer.cancer.gov/statfacts/html/hodg.html
• https://seer.cancer.gov/statfacts/html/nhl.html
• https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=20a16ab2-f338-4abb-9dcd-254bd949a2bc
• https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3904f8dd-1aef-3490-e48f-bd55f32ed67f
• https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f570b9c4-6846-4de2-abfa-4d0a4ae4e394
• https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9b70606e-b99c-4272-a0f1-b5523cce0c59
• https://www.cancer.gov/about-cancer/treatment/side-effects/infection